The effort is designed to raise awareness of RMS — and which is the most common form of MS — as well as the treatment option of Mavenclad (cladribine) tablets, which are produced by the healthcare ...
The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...
Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback